The Life Sciences team advised Aditum Bio and its new portfolio company, Celexor Bio, in an in-licensing transaction with Inmagene Biopharmaceuticals.
Celexor Bio is being formed in connection with the in-licensing of a depleting antibody targeting immunoglobulin-like transcript 7 (ILT7), a highly specific cell surface marker found on plasmacytoid dendritic cells (pDCs), which is anticipated to close later this month. The compound (IMG-018) is being licensed from Inmagene Biopharmaceuticals and will be renamed CLXR-901.
Aditum Bio is committed to improving public health by accelerating R&D in disease areas with both large and more targeted patient populations, where medical innovation can have a significant impact.
The Goodwin team was led by Kingsley Taft and Rachael Bushey, and included Christopher Zhong.
For more details, read the press release and coverage in Endpoints News.